跳至主要内容
临床试验/NCT02896413
NCT02896413已完成不适用

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Yonsei University1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2016年6月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
natural killer cell cytotoxicity

研究概览

简要总结

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ
  • patient scheduled for uterine cancer surgery

排除标准

  • ASA physical status Ⅳ
  • severe hepatorenal disease
  • infection
  • metastasis to other organ
  • problem with communication

研究组 & 干预措施

Dexmedetomidine Group

Experimental

dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery

干预措施: Dexmedetomidine group (Drug)

Control Group

Placebo Comparator

0.9% saline infusion

干预措施: Control group (Drug)

结局指标

主要结局

natural killer cell cytotoxicity

时间窗: postoperative day 5

Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).

次要结局

  • inflammatory response(postoperative day 5)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验